[SCHEDULE 13D/A] 180 Life Sciences Corp. Warrant SEC Filing

Rhea-AI Filing Summary

MongoDB, Inc. (MDB) – Form 4 insider filing dated 07/02/2025

Board director Roelof Botha reported the receipt of additional Class A common shares on 06/30/2025 under the company’s non-employee director compensation program.

• Restricted Stock Units (RSUs): 1,130 units granted at $0 cost. The award vests in full on the earlier of (i) 06/30/2026 or (ii) the 2026 annual meeting, conditional on continued service.
• Stock-in-Lieu of Cash Fees: 246 fully-vested shares issued at $0 cost, calculated using the 30-day VWAP preceding the grant date.

Post-transaction ownership

• Direct holdings: 3,067 Class A shares (previously 1,691).
• Indirect holdings: 217,513 Class A shares held via estate-planning vehicles.

No shares were sold or disposed of, indicating a net increase of 1,376 shares. Because the grants are part of routine board compensation and represent a small fraction of Botha’s existing indirect holdings and MDB’s ~70 million share float, the market impact is expected to be limited. Nevertheless, continued share accumulation by a long-serving director may be viewed as a sign of alignment with shareholder interests.

Positive

• Director increased direct share ownership by 1,376 shares, signaling continued confidence and alignment with shareholders.
• No shares were sold, avoiding negative signaling and potential market overhang.

Negative

• Grant size is immaterial relative to Botha’s total holdings and MongoDB’s float, limiting incremental signaling value.
• Stock received at zero cost; therefore, purchase conviction is less than an open-market buy.

Insights

Equity Research Analyst

TL;DR Insiders added 1,376 shares via routine compensation; positive alignment but immaterial to valuation.

The filing shows Roelof Botha increasing his direct stake by roughly 81%, yet the absolute addition is marginal (<1% of his total MDB exposure and negligible versus the public float). Because the RSUs vest over one year and carry no strike price, dilution is minimal and already incorporated within the company’s equity-based compensation budget. The lack of sales supports a stable insider sentiment, but the transaction does not change fundamentals such as revenue growth, Atlas adoption, or gross margin trajectory. I classify the impact as neutral for valuation purposes.

Corporate Governance Specialist

TL;DR Routine board equity grant reinforces governance best practice; risk/impact low.

Issuing equity to directors aligns incentives with shareholders and is common among high-growth tech issuers. Vest-in-full on the earlier of one year or the 2026 AGM strikes a balance between retention and accountability. The modest size and absence of preferential pricing reduce governance concerns. No Rule 10b5-1 plan is cited, implying open-market flexibility for future dispositions. Overall, the filing signals standard compliance with Section 16(a) and good alignment practices, but it is not materially impactful to investors.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

180 LIFE SCIENCES CORP.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

68236V302

(CUSIP Number)

Blair Jordan
3000 El Camino Real,, Bldg. 4, Suite 200,
Palo Alto, CA, 94306
650-507-0669

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/17/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 68236V302

1

Name of reporting person

Blair Jordan

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 160,000.00
8	Shared Voting Power 1,721,166.00
9	Sole Dispositive Power 160,000.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,888,742.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

31.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 3 below. Percentage ownership is based on 6,039,209 shares of common stock of the Issuer outstanding as of July 1, 2025, as confirmed by the Transfer Agent on such date.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: 180 LIFE SCIENCES CORP.
(c)	Address of Issuer's Principal Executive Offices: 3000 El Camino Real,, Bldg 4, STE 200,, Palo Alto, CALIFORNIA , 94306.
Item 1 Comment: This Amendment No. 3 (the "Amendment") amends and replaces in its entirety the Schedule 13D filed with the Securities and Exchange Commission (the "Commission") by Blair Jordan on February 25, 2025, as amended by Amendment No. 1 thereto filed with the Commission on April 30, 2025 and Amendment No. 2 thereto filed with the Commission on June 20, 2025. This Amendment No. 3 is being filed solely to update and correct the number of restricted stock shares issued to Mr. Jordan on June 17, 2025, as disclosed in Amendment No. 2, which the Board of Directors adjusted, retroactively, in order for the Company to not exceed the total number of shares available for awards under its Third Amended and Restated 2022 Omnibus Incentive Plan.
Item 2.	Identity and Background
(a)	This Statement is being filed by Blair Jordan, the "Reporting Person".
(b)	Mr. Jordan's business address is 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, California, 94306.
(c)	Mr. Jordan's principal business occupation is the Chief Executive Officer of the Issuer.
(d)	The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	The Reporting Person has not, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Mr. Jordan is a citizen of Canada.
Item 3.	Source and Amount of Funds or Other Consideration
	On February 5, 2025, the Issuer, the Reporting Person and Dr. James Woody, entered into a Voting Agreement, whereby Dr. Woody agreed to vote a total of 43,166 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to February 5, 2026, the date after August 5, 2025, that Dr. Woody has sold all of the shares, or the date that the Issuer terminates the Voting Agreement. In order to enforce the terms of the Voting Agreement, Dr. Woody provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 43,166 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 43,166 shares of common stock of the Issuer held by Dr. Woody. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. On February 20, 2025, the Issuer entered into an Executive Consulting Agreement with Mr. Blair Jordan dated February 21, 2025, the Issuer's Chief Executive Officer and director, and Blair Jordan Strategy and Finance Consulting Inc. (an entity owned by Mr. Jordan)("Jordan Consulting" and the "Jordan Consulting Agreement"). The Issuer also agreed to grant 160,000 shares of restricted common stock (the "Shares"), to Mr. Jordan under the Issuer's Third Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan (the "Incentive Plan"), with such Shares to be evidenced and documented by a Notice of Restricted Stock Grant and Restricted Stock Grant Agreement to be entered into between Mr. Jordan and the Issuer, and subject to vesting as follows: (a) 80,000 Shares vest on January 1, 2026, subject to Mr. Jordan's continued service to the Issuer on such vesting date; and (b) 80,000 Shares vest on December 31, 2026, subject to Mr. Jordan's continued service to the Issuer on such vesting date. In the event that the agreement is terminated by the Issuer without "cause" or by Jordan Consulting for "good reason", the Shares and all options and shares then outstanding and scheduled to vest within one year of termination will immediately vest, and (iii) the treatment of the Shares and all options and shares then outstanding and scheduled to vest outside of one year from termination will be determined solely by the Compensation Committee. On February 21, 2025, the Issuer, the Reporting Person and Dr. Marlene Krauss, entered into a Voting Agreement, whereby Dr. Krauss agreed to vote a total of 200,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to August 21, 2025. In order to enforce the terms of the Voting Agreement, Dr. Krauss provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 200,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 200,000 shares of common stock of the Issuer held by Dr. Krauss. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. On April 28, 2025, the Issuer, the Reporting Person and Elray Resources, Inc. ("Elray") entered into a Voting Agreement, whereby Elray agreed to vote a total of 1,318,000 shares of the Issuer's common stock, as recommended by the Board of Directors of the Issuer, at any meeting of stockholders or via any written consent of stockholders, which may occur prior to April 28, 2026. In order to enforce the terms of the Voting Agreement, Elray provided the Reporting Person (or his assigns), solely for the benefit of the Issuer, an irrevocable voting proxy to vote the 1,318,000 shares pursuant to the guidelines set forth above at any meeting of stockholders or via any written consent of stockholders. As a result of the irrevocable voting proxy, Mr. Jordan may be deemed to beneficially own the 1,318,000 shares of common stock of the Issuer held by Elray. Except for the limited right to vote such shares pursuant to the Voting Agreement, Mr. Jordan has no dispositive control over the shares, nor any pecuniary interest therein. Effective June 17, 2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the accelerated vesting of 160,000 shares of restricted common stock originally issued to Mr. Jordan in February 2025, which were to vest at the rate of 1/2 of such shares on each of January 1, 2026 and December 31, 2026, subject to Mr. Jordan's continued service to the Company, and instead provided for such shares to vest in full as of June 17, 2025. Effective June 17, 2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors, approved the grant to Blair Jordan Strategy and Finance Consulting Inc., which entity Mr. Jordan owns and controls, of options to purchase 410,000 shares of common stock, in consideration for services rendered and to be rendered to the Company. The options were granted under the 2025 Option Incentive Plan (the "2025 Plan") and have a term of ten years, subject in all cases to the terms and conditions of the 2025 Plan and the award agreements to be entered into to evidence such grants, and Mr. Jordan's continued service with the Company. The options vest at the rate of 1/2 of such options on each of the six and twelve month anniversaries of the grant date. The options have an exercise price of $0.9290 per share, the closing sales price of the Company's common stock on the Nasdaq Capital Market on June 17, 2025. The 2025 Plan was approved by the Board of Directors, but has not yet been approved by the Company's stockholders, in accordance with the rules of The Nasdaq Capital Market, which allow the Company to adopt an equity arrangement and grant options thereunder prior to obtaining stockholder approval, provided that (i) no options can be exercised prior to obtaining stockholder approval, and (ii) the plan can be unwound, and the outstanding options cancelled, if stockholder approval is not obtained. On June 17, 2025, the Company issued, after recommendation by the Compensation Committee of the Company's Board of Directors and approval by the Board of Directors, 167,576 shares of restricted common stock to Blair Jordan Strategy and Finance Consulting Inc., which entity Mr. Jordan owns and controls, which vest at the rate of 1/2 of such shares on each of the six and twelve month anniversaries of the grant date, subject to Mr. Jordan's continued service to the Company on the applicable vesting dates. The grant is evidenced by a Notice of Restricted Stock Grant and Restricted Stock Grant Agreement entered into between the Company and Mr. Jordan. The grant was made under, and subject to the terms of, the Company's Third Amended and Restated 2022 Omnibus Incentive Plan. All 167,576 of the shares of common stock and 410,000 options discussed above which were granted on June 17, 2025, were issued in the name of Blair Jordan Strategy and Finance Consulting Inc., which entity Mr. Jordan owns and controls, and which shares he is deemed to beneficially own.
Item 4.	Purpose of Transaction
	The information set forth in Item 3 is hereby incorporated by reference into this Item 4. The Reporting Person acquired the securities for investment purposes. In the future, depending on general market and economic conditions affecting the Issuer and other relevant factors, the Reporting Person may purchase additional securities of the Issuer or dispose of some or all of the securities he currently owns from time to time in open market transactions, private transactions or otherwise. The Reporting Person may also acquire additional shares of common stock under various employee benefit and compensation arrangements with the Company in the future. The Reporting Person does not currently have any plans or proposals which relate to or would result in the following described: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure, including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or (j) Any action similar to any of those enumerated above. The Reporting Person retains the right to change his investment intent, and may, from time to time, acquire additional shares of Common Stock or other securities of the Company, or sell or otherwise dispose of (or enter into a plan or arrangements to sell or otherwise dispose of), all or part of the shares of Common Stock or other securities of the Company, if any, beneficially owned by him, in any manner permitted by law. However, the Reporting Person, in his capacity as a member of the Board and Chief Executive Officer may, from time to time, become aware of, initiate, and/or be involved in discussions that relate to the transactions described in this Item 4 and thus retains his right to modify his plans with respect to the transactions described in this Item 4 to acquire or dispose of securities of the Company and to formulate plans and proposals that could result in the occurrence of any such events, subject to applicable laws and regulations.
Item 5.	Interest in Securities of the Issuer
(a)	The aggregate number of shares of Common Stock beneficially owned by the Reporting Person and, the number of shares as to which there is sole power to vote or to direct the voting thereof, shared power to vote or to direct the voting thereof, sole power to dispose or to direct the disposition thereof, or shared power to dispose or to direct the disposition thereof, are set forth on rows 7 through 11 and row 13 of the cover page(s) of this Schedule 13D and are incorporated herein by this reference thereto.
(b)	The aggregate number of shares of Common Stock beneficially owned by the Reporting Person and, for the Reporting Person, the number of shares as to which there is sole power to vote or to direct the voting thereof, shared power to vote or to direct the voting thereof, sole power to dispose or to direct the disposition thereof, or shared power to dispose or to direct the disposition thereof, are set forth on rows 7 through 11 and row 13 of the cover page(s) of this Schedule 13D and are incorporated herein by this reference thereto. As a result of the irrevocable voting proxies described in Item 3, above, Mr. Jordan may be deemed to have the power to vote or to direct the voting of the 1,561,166 shares of common stock of the Issuer subject to such voting proxies and the power to vote or direct the vote of 167,576 shares of common stock held by Blair Jordan Strategy and Finance Consulting Inc.
(c)	The Reporting Person has not effected any transactions in the Common Stock during the past 60 days except as disclosed in Item 3, above, which information is incorporated by reference in this Item 5(c).
(d)	To the knowledge of the Reporting Person, only the Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of the Issuer reported by this Schedule 13D which are held directly by the Reporting Person. The Reporting Person has no power or right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock of the Issuer reported by this Schedule 13D which are the subject of the voting proxies.
(e)	N/A.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information provided in Items 2, 3, 4 and 5 of this Schedule 13D, is hereby incorporated herein by this reference thereto, including, but not limited to the description of the Voting Agreements and the Notice of Restricted Stock Grant and Restricted Stock Grant Agreements.
Item 7.	Material to be Filed as Exhibits.
	1. Voting Agreement dated February 5, 2025, between 180 Life Sciences Corp., James N. Woody and Blair Jordan https://www.sec.gov/Archives/edgar/data/1690080/000121390025011369/ea023028801ex10-2_180life.htm 2. Form of Notice of Restricted Stock Grant and Restricted Stock Grant Agreement (February 2025 Officer and Director Grants) https://www.sec.gov/Archives/edgar/data/1690080/000121390025016103/ea023175801ex10-3_180life.htm 3. Voting Agreement dated February 21, 2025, between 180 Life Sciences Corp., Dr. Marlene Krauss and Blair Jordan https://www.sec.gov/Archives/edgar/data/1690080/000121390025017089/ea023200801ex10-2_180life.htm 4. Voting Agreement dated April 28, 2025, between 180 Life Sciences Corp., Elray Resources, Inc. and Blair Jordan https://www.sec.gov/Archives/edgar/data/1690080/000121390025037115/ea023984401ex10-2_180life.htm 5. 2025 Option Incentive Plan - Form of Stock Option Agreement (June 2025 Awards) https://www.sec.gov/Archives/edgar/data/1690080/000121390025055701/ea024612101ex10-3_180life.htm 6. 2022 Omnibus Incentive Plan - Form of Notice of Restricted Stock Grant and Restricted Stock Grant Agreement - (June 2025 Awards) https://www.sec.gov/Archives/edgar/data/1690080/000121390025055701/ea024612101ex10-4_180life.htm

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blair Jordan

Signature:	/s/ Blair Jordan
Name/Title:	Blair Jordan
Date:	07/02/2025

FAQ

How many MongoDB (MDB) shares did Director Roelof Botha acquire?

He received 1,130 RSUs and 246 fully-vested shares, totaling 1,376 shares.

What is Roelof Botha's total MongoDB share ownership after the transaction?

He now holds 3,067 direct shares and 217,513 indirect shares through estate-planning vehicles.

When will the newly granted RSUs vest?

They vest on the earlier of 06/30/2026 or the date of the 2026 annual shareholder meeting.

Did the director sell any MongoDB shares in this Form 4?

No. The filing reports only acquisitions; no dispositions were made.

Is this Form 4 expected to affect MongoDB's stock price?

The transaction is routine and small relative to float, so market impact should be minimal.